The Experts below are selected from a list of 10857 Experts worldwide ranked by ideXlab platform
Raphael Ronel - One of the best experts on this subject based on the ideXlab platform.
-
ultrasonic control without Hormone Determination for ovulation induction in in vitro fertilization embryo transfer with gonadotrophin releasing Hormone analogue and human menopausal gonadotrophin
Human Reproduction, 1994Co-Authors: A. Golan, A. Herman, Yigal Soffer, Ian Bukovsky, Raphael RonelAbstract:A total of 114 patients admitted to an in-vitro fertilization-embryo transfer programme for the first time, were randomly assigned to the study group or controls. Gonadotrophin-releasing Hormone analogue (GnRHa) and human menopausal gonadotrophin (HMG) were used for ovulation induction. The study patients were followed up merely by ultrasonography and the controls by ultrasonography and serum Determinations of oestradiol, progesterone and luteinizing Hormone (LH). There was no significant difference in the duration and total amount of HMG used for ovulation induction (10.9 versus 11.5 days and 34.8 versus 37.9 ampoules, respectively). The number of oocytes retrieved (11.7 versus 13.4) and the numbers of embryos replaced (2.6 versus 2.8) and cryopreserved (1.9 versus 3.3) were also similar. Pregnancy rates were similar. Pregnancy rate per ovum retrieval was 22.2 versus 25% and per embryo transfer 27.2 versus 26.5%. Oestradiol patterns were also similar. The rate and severity of ovarian hyperstimulation syndrome were virtually identical. We conclude that 'ultrasound-only' monitoring of ovulation induction in IVF cycles treated by GnRHa-HMG in the long protocol is as effective and safe as the conventional ultrasound and Hormone Determination, but far simpler, swifter and more cost-effective.
A. Golan - One of the best experts on this subject based on the ideXlab platform.
-
ultrasonic control without Hormone Determination for ovulation induction in in vitro fertilization embryo transfer with gonadotrophin releasing Hormone analogue and human menopausal gonadotrophin
Human Reproduction, 1994Co-Authors: A. Golan, A. Herman, Yigal Soffer, Ian Bukovsky, Raphael RonelAbstract:A total of 114 patients admitted to an in-vitro fertilization-embryo transfer programme for the first time, were randomly assigned to the study group or controls. Gonadotrophin-releasing Hormone analogue (GnRHa) and human menopausal gonadotrophin (HMG) were used for ovulation induction. The study patients were followed up merely by ultrasonography and the controls by ultrasonography and serum Determinations of oestradiol, progesterone and luteinizing Hormone (LH). There was no significant difference in the duration and total amount of HMG used for ovulation induction (10.9 versus 11.5 days and 34.8 versus 37.9 ampoules, respectively). The number of oocytes retrieved (11.7 versus 13.4) and the numbers of embryos replaced (2.6 versus 2.8) and cryopreserved (1.9 versus 3.3) were also similar. Pregnancy rates were similar. Pregnancy rate per ovum retrieval was 22.2 versus 25% and per embryo transfer 27.2 versus 26.5%. Oestradiol patterns were also similar. The rate and severity of ovarian hyperstimulation syndrome were virtually identical. We conclude that 'ultrasound-only' monitoring of ovulation induction in IVF cycles treated by GnRHa-HMG in the long protocol is as effective and safe as the conventional ultrasound and Hormone Determination, but far simpler, swifter and more cost-effective.
-
Ultrasonic control without Hormone Determination for ovulation induction in in-vitro fertilization/embryo transfer with gonadotrophin-releasing Hormone analogue and human menopausal gonadotrophin.
Human reproduction (Oxford England), 1994Co-Authors: A. Golan, A. Herman, Yigal Soffer, Ian Bukovsky, Raphael Ron-elAbstract:A total of 114 patients admitted to an in-vitro fertilization-embryo transfer programme for the first time, were randomly assigned to the study group or controls. Gonadotrophin-releasing Hormone analogue (GnRHa) and human menopausal gonadotrophin (HMG) were used for ovulation induction. The study patients were followed up merely by ultrasonography and the controls by ultrasonography and serum Determinations of oestradiol, progesterone and luteinizing Hormone (LH). There was no significant difference in the duration and total amount of HMG used for ovulation induction (10.9 versus 11.5 days and 34.8 versus 37.9 ampoules, respectively). The number of oocytes retrieved (11.7 versus 13.4) and the numbers of embryos replaced (2.6 versus 2.8) and cryopreserved (1.9 versus 3.3) were also similar. Pregnancy rates were similar. Pregnancy rate per ovum retrieval was 22.2 versus 25% and per embryo transfer 27.2 versus 26.5%. Oestradiol patterns were also similar. The rate and severity of ovarian hyperstimulation syndrome were virtually identical. We conclude that 'ultrasound-only' monitoring of ovulation induction in IVF cycles treated by GnRHa-HMG in the long protocol is as effective and safe as the conventional ultrasound and Hormone Determination, but far simpler, swifter and more cost-effective.
Vinicius Nahime Brito - One of the best experts on this subject based on the ideXlab platform.
-
early onset of primary hypogonadism revealed by serum anti mullerian Hormone Determination during infancy and childhood in trisomy 21
International Journal of Andrology, 2011Co-Authors: Romina P Grinspon, Patricia Bedecarras, Maria Gabriela Ballerini, German Iniguez, Ana Rocha, E Mantovani Rodrigues A Resende, Vinicius Nahime Brito, C Milani, Figueroa V Gacitua, Ana ChiesaAbstract:Summary Male patients with an extra sex chromosome or autosome are expected to present primary hypogonadism at puberty owing to meiotic germ-cell failure. Scarce information is available on trisomy 21, a frequent autosomal aneuploidy. Our objective was to assess whether trisomy 21 presents with pubertal-onset, germ-cell specific, primary hypogonadism in males, or whether the hypogonadism is established earlier and affects other testicular cell populations. We assessed the functional status of the pituitary-testicular axis, especially Sertoli cell function, in 117 boys with trisomy 21 (ages: 2 months–20 year). To compare with an adequate control population, we established reference levels for serum anti-Mullerian Hormone (AMH) in 421 normal males, from birth to adulthood, using a recently developed ultrasensitive assay. In trisomy 21, AMH was lower than normal, indicating Sertoli cell dysfunction, from early infancy, independently of the existence of cryptorchidism. The overall prevalence rate of AMH below the 3rd percentile was 64.3% in infants with trisomy 21. Follicle-stimulating Hormone was elevated in patients <6 months and after pubertal onset. Testosterone was within the normal range, but luteinizing Hormone was elevated in most patients <6 months and after pubertal onset, indicating a mild Leydig cell dysfunction. We conclude that in trisomy 21, primary hypogonadism involves a combined dysfunction of Sertoli and Leydig cells, which can be observed independently of cryptorchidism soon after birth, thus prompting the search for new hypotheses to explain the pathophysiology of gonadal dysfunction in autosomal trisomy.
-
a single luteinizing Hormone Determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin dependent precocious puberty in girls
The Journal of Clinical Endocrinology and Metabolism, 2004Co-Authors: Vinicius Nahime Brito, Ana Claudia Latronico, Ivo J P Arnhold, Berenice B MendoncaAbstract:Long-acting GnRH analogs represent the standard treatment for gonadotropin-dependent precocious puberty. The aim of this study was to determine the hormonal parameters for monitoring the adequacy of depot leuprolide acetate treatment in girls with clinical and hormonal diagnosis of gonadotropin-dependent precocious puberty. Eighteen girls were treated monthly with 3.75 mg depot leuprolide acetate. Adequate hypothalamic-pituitary-gonadal axis suppression during treatment was achieved in 16 of the 18 girls according to the clinical parameters and prepubertal LH levels. In these 16 well-controlled girls, the LH peak after a classical GnRH test was compared with a single LH measurement obtained 2 h after depot leuprolide acetate administration before and during GnRH analog treatment. Before therapy, the mean ± sd LH peak after a classical GnRH test was 18.4 ± 11.2 IU/liter (ranging from 7–41.5 IU/liter), and it was 22.6 ± 8.3 IU/liter 2 h after the first depot leuprolide dose (ranging from 10–35.3 IU/liter). ...
K.a. Rafferty - One of the best experts on this subject based on the ideXlab platform.
-
Sex steroid Hormone Determination of the maternal brain: effects beyond reproduction.
Mini reviews in medicinal chemistry, 2012Co-Authors: C.h. Kinsley, E. Meyer, K.a. RaffertyAbstract:Herein we discuss the effects of Hormones on reproduction, but with a focus on the ripples that emanate from the main effects. That is, the role of Hormones in reproductive events is both well-known and well accepted; less studied and understood are effects that appear to be ancillary to the primary objectives of the hormonal effects, which support, complement and extend their primary effects. We present evidence for how the hormonal stimulation of pregnancy constructs the maternal brain; makes it more efficient; enhances cognition; regulates stress responsiveness; modifies sensory systems (we discuss mainly olfaction); neurogenesis; and learning. Thus, steroid and other Hormones and neuropeptides restructure the nervous system, particularly of females, to produce and regulate maternal behavior as well as behaviors and physiological systems that contribute to and support what is arguably the primary function of the Hormones: survival and effective nurturance of the female’s metabolic and genetic investment.
Ana Chiesa - One of the best experts on this subject based on the ideXlab platform.
-
early onset of primary hypogonadism revealed by serum anti mullerian Hormone Determination during infancy and childhood in trisomy 21
International Journal of Andrology, 2011Co-Authors: Romina P Grinspon, Patricia Bedecarras, Maria Gabriela Ballerini, German Iniguez, Ana Rocha, E Mantovani Rodrigues A Resende, Vinicius Nahime Brito, C Milani, Figueroa V Gacitua, Ana ChiesaAbstract:Summary Male patients with an extra sex chromosome or autosome are expected to present primary hypogonadism at puberty owing to meiotic germ-cell failure. Scarce information is available on trisomy 21, a frequent autosomal aneuploidy. Our objective was to assess whether trisomy 21 presents with pubertal-onset, germ-cell specific, primary hypogonadism in males, or whether the hypogonadism is established earlier and affects other testicular cell populations. We assessed the functional status of the pituitary-testicular axis, especially Sertoli cell function, in 117 boys with trisomy 21 (ages: 2 months–20 year). To compare with an adequate control population, we established reference levels for serum anti-Mullerian Hormone (AMH) in 421 normal males, from birth to adulthood, using a recently developed ultrasensitive assay. In trisomy 21, AMH was lower than normal, indicating Sertoli cell dysfunction, from early infancy, independently of the existence of cryptorchidism. The overall prevalence rate of AMH below the 3rd percentile was 64.3% in infants with trisomy 21. Follicle-stimulating Hormone was elevated in patients <6 months and after pubertal onset. Testosterone was within the normal range, but luteinizing Hormone was elevated in most patients <6 months and after pubertal onset, indicating a mild Leydig cell dysfunction. We conclude that in trisomy 21, primary hypogonadism involves a combined dysfunction of Sertoli and Leydig cells, which can be observed independently of cryptorchidism soon after birth, thus prompting the search for new hypotheses to explain the pathophysiology of gonadal dysfunction in autosomal trisomy.